Found: 5
Select item for more details and to access through your institution.
Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib.
- Published in:
- Mediators of Inflammation, 2020, p. 1, doi. 10.1155/2020/1835836
- By:
- Publication type:
- Article
Extracellular Nucleotides Affect the Proangiogenic Behavior of Fibroblasts, Keratinocytes, and Endothelial Cells.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 1, p. 238, doi. 10.3390/ijms23010238
- By:
- Publication type:
- Article
The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib.
- Published in:
- Cancers, 2021, v. 13, n. 5, p. 951, doi. 10.3390/cancers13050951
- By:
- Publication type:
- Article
The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients.
- Published in:
- Cancers, 2020, v. 12, n. 9, p. 2569, doi. 10.3390/cancers12092569
- By:
- Publication type:
- Article
Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 1, p. 112, doi. 10.3390/jcm11010112
- By:
- Publication type:
- Article